" class="no-js "lang="en-US"> Garret Hampton - Medtech Alert
Thursday, March 28, 2024
Garret Hampton

Garret Hampton

About Garret Hampton

Garret Hampton joined Illumina in 2017 and leads the company’s Clinical Genomics group, which includes Clinical Assay Development, Regulatory, Clinical Product Marketing, Market Development, Lab Services, and Clinical Research groups, as well as the Office of the Chief Medical Officer.

Before joining Illumina, he held a variety of leadership positions at Genentech, Inc., and was most recently Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics. He previously held scientific and management roles at Celgene Corporation, Genomics Institute of the Novartis Research Foundation, and Genos Biosciences.

Hampton holds a BA in natural sciences and genetics and an MA in natural sciences from Trinity College in Dublin, Ireland, and a PhD in cancer genetics from Imperial Cancer Research Fund and University College London

Related Story

FDA Approves First NGS-based Companion Diagnostic to Aid in Selecting Non-small Cell Lung Cancer Patients With HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for Treatment With ENHERTU

August 15 2022

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine […]

FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue

December 10 2021

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific‘s Oncomine Dx Target […]

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations

September 17 2021

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific‘s […]

Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics

September 2 2021

Thermo Fisher Scientific‘s clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing […]